Eleven Therapeutics is a startup at the forefront of mRNA therapeutics innovation.
The company’s xRNA modality-based pipeline is aimed to create extended-release mRNA therapeutics (xRNA) targeting unmet medical needs in metabolic, hematologic, and infectious disease areas. TERÅ is a proprietary high-throughput platform designed to screen thousands of xRNA molecules in order to identify non-canonical elements that possess superior stability and safety characteristics, amenable for a multitude of chronic therapeutic applications, including the newly announced fibrotic disorders.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Eleven Therapeutics Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jan 11, 2024
www.prnewswire.com
Eleven Therapeutics Welcomes Dr. Paloma H Giangrande as Chief Technology Officer
#Management Changes
Jan 9, 2024
www.businesskorea.co.kr
Dong-A ST Signs R&D Agreement with Eleven Therapeutics for RNA-based Gene Therapy
#Partners, Expand
Jul 16, 2023
www.pharmaceutical-technology.com
Eleven and Novo Nordisk partner to develop nucleic acid therapeutics - Pharmaceutical Technology
#Partners, Investment
Mar 26, 2023
www.calcalistech.com
"We are revolutionizing the world of RNA" | CTech
undefined
Aug 2, 2022
www.finsmes.com
Eleven Therapeutics Raises $22M in Seed Funding - FinSMEs